ENOV Enovis CORP
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1420800 · Fiscal year ends 12/31
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.3%
TTM net income YoY61.4%
TTM EPS YoY62.1%
Revenue 3-yr CAGR11.6%
Net income 3-yr CAGR—
Margins
Gross margin61.3%
Operating margin-20.6%
Net margin-22.9%
FCF margin3.0%
EBITDA margin37.7%
Returns
ROE-30.0%
ROA-12.9%
ROIC (approx.)-12.3%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets60.0%
Debt / equity0.84x
Current ratio2.15x
Interest coverage-14.69x
Cash quality & payout
Operating cash flow / net income-0.49x
Accruals ratio-19.3%
Payout ratio—
Capex / revenue8.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-02 | 2026Q22026-07-03 | 2026Q12026-04-03 | 2025Q4*2025-12-31 | 2025Q32025-10-03 | 2025Q22025-07-04 | 2025Q12025-04-04 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $558.73M | $582.78M | $589.15M | $575.76M | $548.91M | $564.54M | $558.83M | $560.98M |
| Cost of revenue | $218.88M | $223.53M | $223.67M | $226.34M | $220.00M | $229.85M | $226.60M | $253.46M |
| Gross profit | $339.85M | $359.25M | $365.49M | $349.42M | $328.91M | $334.70M | $332.23M | $307.52M |
| R&D expense | $31.27M | $31.69M | $31.53M | $31.36M | $29.74M | $30.70M | $28.53M | $23.95M |
| SG&A expense | $259.38M | $263.73M | $282.81M | $270.44M | $263.62M | $267.07M | $269.02M | $257.71M |
| Operating income | $3.38M | $17.41M | $6.53M | -$502.18M | -$558.49M | -$16.80M | -$46.77M | -$664.75M |
| Interest expense | $7.62M | $8.04M | $9.17M | $7.51M | $8.83M | $9.29M | $9.19M | $9.07M |
| Pretax income | -$456,000 | $7.46M | $634,000 | -$509.55M | -$566.87M | -$25.65M | -$57.35M | -$673.73M |
| Income tax | -$1.68M | $8.50M | $9.04M | $9.26M | $4.00M | $10.80M | -$1.77M | $29.90M |
| Net income | $3.14M | -$1.19M | -$8.76M | -$520.59M | -$571.15M | -$36.74M | -$55.97M | -$703.34M |
| EBITDA | $76.88M | $88.44M | $79.89M | $624.58M | -$484.11M | $54.76M | $24.67M | $52.69M |
| EPS (basic) | 0.06 | -0.02 | -0.15 | — | -9.99 | -0.64 | -0.98 | — |
| EPS (diluted) | 0.06 | -0.02 | -0.15 | — | -9.99 | -0.64 | -0.98 | — |
| Weighted avg. shares (diluted) | 58.49M | 57.60M | 57.31M | — | 57.17M | 57.13M | 56.79M | — |
| Banking | ||||||||
| Net interest income | -$7.62M | -$8.04M | -$9.17M | — | -$8.83M | -$9.29M | -$9.19M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $13.04M | $12.56M | $33.13M | $36.39M | $33.62M | $44.07M | $38.46M | $48.17M |
| Receivables | $428.29M | $441.85M | $444.21M | $442.79M | $431.77M | $453.70M | $435.62M | $407.03M |
| Inventory | $620.15M | $601.66M | $602.54M | $584.38M | $613.75M | $628.22M | $585.91M | $547.12M |
| Current assets | $1.25B | $1.21B | $1.24B | $1.21B | $1.28B | $1.28B | $1.22B | $1.15B |
| PP&E, net | $526.32M | $527.53M | $519.72M | $507.06M | $486.42M | $460.13M | $426.29M | $404.50M |
| Goodwill | $702.09M | $709.85M | $711.90M | $718.30M | $1.22B | $1.78B | $1.73B | $1.69B |
| Intangibles | $1.09B | $1.15B | $1.19B | $1.24B | $1.28B | $1.34B | $1.34B | $1.32B |
| Total assets | $3.74B | $3.77B | $3.83B | $3.83B | $4.43B | $5.02B | $4.88B | $4.72B |
| Current liabilities | $579.84M | $612.05M | $608.66M | $598.47M | $575.44M | $568.18M | $477.42M | $529.00M |
| Short-term debt | $35.00M | $37.39M | $35.00M | $35.00M | $20.00M | $20.03M | $20.03M | $20.03M |
| Long-term debt | $1.22B | $1.25B | $1.29B | $1.26B | $1.34B | $1.37B | $1.37B | $1.31B |
| Total debt | $1.26B | $1.28B | $1.33B | $1.30B | $1.36B | $1.39B | $1.39B | $1.33B |
| Total liabilities | $2.24B | $2.29B | $2.35B | $2.34B | $2.41B | $2.44B | $2.25B | $2.15B |
| Shareholders' equity | $1.49B | $1.48B | $1.48B | $1.49B | $2.02B | $2.58B | $2.62B | $2.56B |
| Net debt | $1.25B | $1.27B | $1.29B | $1.26B | $1.33B | $1.35B | $1.35B | $1.28B |
| Shares outstanding | 57.69M | 57.67M | 57.55M | 57.19M | 57.19M | 57.16M | 57.12M | 55.88M |
| Cash flow statement | ||||||||
| Operating cash flow | $71.49M | $75.03M | $23.95M | $88.54M | $82.58M | $47.77M | -$1.60M | $88.33M |
| Capital expenditure | $36.51M | $43.90M | $52.80M | $56.25M | $53.49M | $44.37M | $43.26M | $53.19M |
| Free cash flow | $34.99M | $31.14M | -$28.85M | $32.29M | $29.09M | $3.40M | -$44.86M | $35.14M |
| Investing cash flow | -$42.50M | -$45.01M | -$53.09M | -$12.99M | -$56.06M | -$49.80M | -$60.52M | -$57.88M |
| Financing cash flow | -$28.50M | -$50.56M | $26.02M | -$72.92M | -$36.91M | $6.23M | $51.19M | -$20.08M |
| Depreciation & amortization | $73.50M | $71.03M | $73.36M | $1.13B | $74.38M | $71.55M | $71.44M | $717.44M |
| Stock-based compensation | $7.54M | $8.90M | $8.75M | $8.11M | $8.96M | $8.67M | $7.41M | $7.73M |
Free plan shows the latest 8 periods; Pro shows all 68 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.